IXICO PLC is primarily active in the healthcare and pharmaceutical industries.

The main competitors of IXICO PLC in the market include companies such as Biogen Inc., Evidera, and ICON plc.

IXICO PLC is a leading provider of digital technologies to the global pharmaceutical industry. Established in 2004, IXICO's expertise lies in utilizing artificial intelligence and machine learning to derive valuable insights from medical imaging and digital biomarker data. The company specializes in providing clinical trial services and neuroimaging analysis solutions, enabling efficient and accurate assessment of neurodegenerative diseases. With a strong focus on research and development, IXICO's innovative technologies have been employed in several clinical trials worldwide. Over the years, IXICO has earned a reputation for its cutting-edge solutions, contributing significantly to advancements in precision medicine.

IXICO PLC has achieved several significant milestones. Notably, the company has made considerable progress in the field of data analytics and biomarker services for neuroscience clinical trials. IXICO PLC has successfully developed and validated novel algorithms and software platforms that provide accurate and reliable biomarker measurements. Additionally, the company has established strong partnerships with leading pharmaceutical and biotech companies, providing them with valuable insights and support in their research and development efforts. Moreover, IXICO PLC has consistently demonstrated its commitment to innovation and excellence, earning recognition and accolades from the industry.

IXICO PLC is primarily present in the United Kingdom, the United States, and Europe.

IXICO PLC represents core values of innovation, scientific excellence, and data-driven solutions in the field of data analytics for neuroscience. The company upholds a corporate philosophy focused on enhancing clinical research outcomes through advanced technology and specialized expertise. By leveraging its proprietary imaging and digital biomarker platform, IXICO PLC enables pharmaceutical companies and research organizations to better understand diseases affecting the brain. Their commitment to reliable and high-quality data analysis supports the development of novel treatments and therapies. With a strong emphasis on collaboration and continuous improvement, IXICO PLC strives to make a meaningful impact in neuroscience research and contribute to improving patients' lives.

Analysts currently set an average price target of 26,52 GBP for the IXICO stock (median: 26,52 GBP), implying +231,5 % versus the latest price. The consensus is based on 9 analyst ratings.

IXICO Analyytikkojen kursstavoitteet 2026

9 analysts currently rate the IXICO stock: 8 recommend buying, 1 holding and 0 selling. For 2026, analysts expect IXICO to generate revenue of 7,73 M GBP and earnings per share of −0,02 GBP.

IXICO Analyytikkojen kursstavoitteet 2026

Converted at the current exchange rate, the IXICO share trades at 0,09 EUR (0,08 GBP).

The IXICO share (IXI.L) is listed on 4 stock exchanges, including: Frankfurt (PYPB.F), London (IXI.L), London (IXI.L).

IXICO PLC is a company specialized in digital health, with a business model that aims to offer innovative solutions for supporting clinical trials and diagnosing neurological diseases. The company is divided into different divisions, each offering specific products and services. The first division of IXICO is contract research. The company provides a comprehensive range of services to support companies in conducting clinical trials. This includes brain imaging, quantitative data analysis, and statistical evaluation of studies. Customers such as pharmaceutical and biotech companies can benefit from the company's expertise to evaluate the effectiveness of drugs and optimize study designs. Another division of IXICO is software solutions. The company develops and markets a wide range of software products aimed at supporting the diagnosis and monitoring of neurodegenerative diseases. The product range includes automated image analysis tools and algorithms for analyzing data obtained from neurological imaging techniques such as MRI and CT. Another division of the company is the provision of clinical trials to patients, as well as medical education. IXICO offers expertise and support in study design, decision-making, and the conduct of clinical trials. This can include training sessions and educational materials. The company primarily specializes in neurological diseases, such as multiple sclerosis, Alzheimer's, stroke, and Parkinson's. However, applications for diagnosing diseases affecting the nervous system are also a focus of the company. Overall, IXICO brings together a wealth of expertise that is crucial in the research, diagnosis, and treatment of neurological diseases. This includes scientific expertise in imaging techniques and statistics, as well as a comprehensive range of software products aimed at diagnosing neurological diseases more accurately and quickly. The company is dedicated to contributing to better treatment for patients worldwide and advancing medicine in the field of neurological diseases.

odotettu liikevaihto IXICO on 7,73 M GBP. Tämä luku perustuu nykyisiin talousarvoihin ja heijastaa yhtiön liiketoimintasuoritusta.

odotettu voitto IXICO on −1,66 M GBP. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.

IXICO:n hinta-voitto-suhde (P/E) on tällä hetkellä −4,31. P/E-suhde vertaa nykyistä osakekurssia osakekohtaiseen tulokseen ja auttaa sijoittajia arvioimaan IXICO-osakkeen arvostusta.

IXICO:n hinta-myynti-suhde (P/S) on tällä hetkellä 0,93. P/S-suhde vertaa markkina-arvoa vuosittaisiin tuloihin ja toimii IXICO-osakkeen arvostuskennuslukuna.

IXICO:n Eulpool-laatuscore on 2/10.

IXICO:n ISIN on GB00BFXR4C20. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.

IXICO:n WKN on A2N478. WKN (Wertpapierkennnummer) on kuusinumeroinen saksalainen arvopaperin tunnus.

IXICO:n ticker on IXI.L. Tämä pörssinoteeraus käytetään IXICO-osakkeiden kauppaan pörssissä.

IXICO maksoi osinkoa joka vuosi viimeisten 0 vuoden aikana.

IXICO kuuluu sektoriin 'Terveydenhuolto'.

IXICO:n osingot jaetaan valuutassa GBP.